Loading clinical trials...

Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP) | Clinical Trials | Clareo Health

RECRUITING

Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)

Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Advanced Prostate Cancer (CaP)

NCT06470750•Mayo Clinic

View on ClinicalTrials.gov

Summary

This study evaluates the possibility of patient-centered home care as a new model of cancer care to reduce disparities and improve health related quality of life and patient-reported outcomes in Black patients with prostate cancer.

Detailed Description

PRIMARY OBJECTIVES: I. To evaluate a highly innovative project evaluating the feasibility of patient-centered home care PCHC as a new model of cancer care to reduce disparities and improve health related QoL (HRQoL) and patient reported-outcomes (PROs) in Black patients with advanced prostate cancer (CaP). (Phase I) II. Establish patient-centeredness by exploring patients' choice relative to the place of CaP treatment for certain aspects of therapy as well as end-of-life care. III. Establish the acceptance and impact of PCHC on PROs and HRQoL in BM with advanced CaP. OUTLINE: This is an observational study. Participants are assigned to 1 of 2 groups. GROUP 1: Participants take part in a focus group or complete questionnaires and may take part in an interview on study. GROUP 2: Participants complete questionnaires throughout the study.

Eligibility

Age

18 - No limit years

Sex

MALE

Healthy Volunteers

Yes

Inclusion Criteria

•GROUP 1 FOCUS GROUPS:
•* Individuals identifying as Black and male who are familiar with the landscape of medical care and cancer
•GROUP 1 SURVEYS:
•* Are 18 years of age or older
•* Have histologic evidence of prostate adenocarcinoma
•* Are requiring, have required, or will require prostate cancer treatment
•* Have an understanding of the protocol and its requirements
•* Are willing to fill in a questionnaire and participate in a focused interview
•* Are able and willing to sign an informed consent
•GROUP 1 INTERVIEWS:
+9 more criteria

Exclusion Criteria

•GROUP 1 FOCUS GROUPS:
•* Individuals who do not identify as Black or male or who have had no extensive interaction with the healthcare system
•GROUP 1 SURVEYS:
•* Do not identify as Black men
•* Have not been diagnosed with prostate cancer
•GROUP 1 INTERVIEWS:
•* Not enrolled in the survey phase of the protocol
•GROUP 2:
•* Do not identify as Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges)
•* Have not been diagnosed with histologic evidence of prostate adenocarcinoma
+1 more criteria

Locations (1)

Mayo Clinic in Florida

Jacksonville, Florida, United States

Key Dates

Start Date

July 25, 2024

Primary Completion Date

July 30, 2026

Completion Date

July 30, 2026

Last Updated

January 20, 2026

Enrollment

ESTIMATED participants

Conditions

Prostate Adenocarcinoma

Interventions

Non-Interventional Study

OTHER

Contacts

Clinical Trials Referral Office

CONTACT

855-776-0015 mayocliniccancerstudies@mayo.edu

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

NCT05691465

Metastatic Prostate Adenocarcinoma With Neuroendocrine DifferentiationMetastatic Prostate Neuroendocrine Carcinoma+2 more

View study

RECRUITINGPHASE3

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

NCT06205316

Biochemically Recurrent Prostate CarcinomaOligometastatic Prostate Carcinoma+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 20, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)

Inclusion Criteria

Exclusion Criteria

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Personalized Optimization of Systematic Prostate Biopsy